Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
| ▸ | NOS3 | P29474 | 4/20 | 0.51 |
| ▸ | NOS1 | P29475 | 4/20 | 0.51 |
| ▸ | NOS2 | P35228 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
| ▸ | BPTF | Q12830 | 9/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216229 | 0.91 | HTR2C (0.61) | PRKCINOS3NOS1NOS2HTR2A | |
| SCHEMBL30411128 | 0.91 | HTR2C (0.61) | PRKCINOS3NOS1NOS2HTR2A | |
| SCHEMBL1121913 | 0.84 | NOS3 (0.53) | NOS3NOS1NOS2HTR2AHTR2C | |
| SCHEMBL5089820 | 0.83 | PRKCI (0.56) | PRKCIHTR2AHTR2CPLGPLAU | |
| SCHEMBL16741930 | 0.82 | EGFR (0.53) | NOS3NOS1NOS2HTR2AHTR2C | |
| SCHEMBL8127772 | 0.81 | HTR2C (0.68) | NOS3NOS1NOS2HTR2AHTR2C | |
| SCHEMBL31312599 | 0.80 | PRKCI (0.53) | PRKCIPLGPLAUEGFR | |
| SCHEMBL3650822 | 0.79 | PRKCI (0.59) | PRKCIHTR2AHTR2CPLGPLAU | |
| SCHEMBL4007913 | 0.79 | SCN9A (0.55) | PRKCINOS3NOS1NOS2HTR2A | |
| SCHEMBL30408910 | 0.79 | SCN9A (0.55) | PRKCINOS3NOS1NOS2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| EP-3074378-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen Ltd. (AU) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015074123-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2015-05-28 | — | — | WO | disclosed |
| EP-1178953-B1 | AROMATIC AMIDES | WARNER LAMBERT CO (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1178953-A1 | AROMATIC AMIDES | WARNER-LAMBERT COMPANY (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000068184-A1 | AROMATIC AMIDES | WARNER-LAMBERT COMPANY (US) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | PRKCI 1438/4885NOS3 995/4885NOS1 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.